Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?,Pharmaceutical Research

当前位置： X-MOL 学术 › Pharm. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?
Pharmaceutical Research ( IF 3.5 ) Pub Date : 2022-09-02 , DOI: 10.1007/s11095-022-03380-1
Timothy Qi ₁ , Tyler Dunlap ₁ , Yanguang Cao _{1,

2}

Affiliation

Project Optimus is a US Food and Drug Administration (FDA) initiative to reform dose selection in oncology drug development. Here, we focus on tumor evolution, a broadly observed phenomenon that invariably leads to therapeutic failure and disease relapse, and its effect on the exposure–response (E-R) relationships of oncology drugs. We propose a greater emphasis on tumor evolution during clinical development to facilitate the selection of optimal doses for molecularly targeted therapies and immunotherapies in oncology.

中文翻译：

拥抱 Project Optimus：我们可以利用进化论来优化肿瘤学的剂量吗？

Optimus 项目是美国食品和药物管理局 (FDA) 发起的一项改革肿瘤药物开发剂量选择的倡议。在这里，我们关注肿瘤演变，这是一种广泛观察到的现象，总是导致治疗失败和疾病复发，以及它对肿瘤药物的暴露-反应 (ER) 关系的影响。我们建议在临床开发过程中更加强调肿瘤的演变，以促进选择最佳剂量用于肿瘤学中的分子靶向治疗和免疫治疗。

更新日期：2022-09-04

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南